PTH(1-34) for Surgical Hypoparathyroidism: A 2-Year Prospective, Open-Label Investigation of Efficacy and Quality of Life.

Palermo A, Santonati A, Tabacco G, Bosco D, Spada A, Pedone C, Raggiunti B, Doris T, Maggi D, Grimaldi F, Manfrini S, Vescini F

The Journal of clinical endocrinology and metabolism1 Jan 2018Cited by 52 (Europe PMC)

PMID29099939DOI10.1210/jc.2017-01555PepBankPUB-29099939

Source link PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanNon-randomized trialEfficacy outcome
In adults with postoperative hypoparathyroidism, PTH(1-34) increased serum calcium from baseline to 3 months, with subsequent stability.
In plain wordsIn adults with postoperative hypoparathyroidism, teriparatide increased blood calcium compared with baseline, then levels remained stable.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSerum calcium
Study
n = 42
Comparator
Baseline
Outcome group
Electrolyte balance · Endocrine and hormones
Studied dose
20 μg twice daily · subcutaneous injection · 24 monthsAs given in this study (human).
Measurements
Serum calcium
7.6 mg/dL
baseline
Serum calcium
8.9 mg/dL
3 months
Source sentences
Summary
Mean serum calcium concentration significantly increased from baseline to 3 months (7.6 ± 0.6 vs 8.9 ± 1.1 mg/dL, P < 0.001) and remained stable until the end of the study, despite reductions in calcium and vitamin D supplementation.
4 context sentences(design, population, supporting numbers)
Summary · context
To investigate the effects of 24-month PTH(1-34) treatment in a homogeneous cohort of adult subjects with postoperative hypoparathyroidism and to evaluate QOL changes.
Summary · context
Prospective open-label study.
Summary · context
42 subjects.
Summary · context
Twice-daily PTH(1-34) 20 μg subcutaneous injection.
Report a problemFND-2909993901
02HumanNon-randomized trialEfficacy outcome
In adults with postoperative hypoparathyroidism, calcium supplementation decreased during PTH(1-34) therapy.
In plain wordsIn adults with postoperative hypoparathyroidism, calcium supplementation decreased during teriparatide treatment compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseCalcium supplementation requirement
Study
n = 42
Comparator
Baseline
Outcome group
Electrolyte balance · Endocrine and hormones
Studied dose
20 μg twice daily · subcutaneous injection · 24 monthsAs given in this study (human).
Source sentences
Summary
Mean serum calcium concentration significantly increased from baseline to 3 months (7.6 ± 0.6 vs 8.9 ± 1.1 mg/dL, P < 0.001) and remained stable until the end of the study, despite reductions in calcium and vitamin D supplementation.
4 context sentences(design, population, supporting numbers)
Summary · context
To investigate the effects of 24-month PTH(1-34) treatment in a homogeneous cohort of adult subjects with postoperative hypoparathyroidism and to evaluate QOL changes.
Summary · context
Prospective open-label study.
Summary · context
42 subjects.
Summary · context
Twice-daily PTH(1-34) 20 μg subcutaneous injection.
Report a problemFND-2909993902
03HumanNon-randomized trialEfficacy outcome
In adults with postoperative hypoparathyroidism, vitamin D supplementation decreased during PTH(1-34) therapy.
In plain wordsIn adults with postoperative hypoparathyroidism, vitamin D supplementation decreased during teriparatide treatment compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseVitamin D supplementation requirement
Study
n = 42
Comparator
Baseline
Outcome group
Electrolyte balance · Endocrine and hormones
Studied dose
20 μg twice daily · subcutaneous injection · 24 monthsAs given in this study (human).
Source sentences
Summary
Mean serum calcium concentration significantly increased from baseline to 3 months (7.6 ± 0.6 vs 8.9 ± 1.1 mg/dL, P < 0.001) and remained stable until the end of the study, despite reductions in calcium and vitamin D supplementation.
4 context sentences(design, population, supporting numbers)
Summary · context
To investigate the effects of 24-month PTH(1-34) treatment in a homogeneous cohort of adult subjects with postoperative hypoparathyroidism and to evaluate QOL changes.
Summary · context
Prospective open-label study.
Summary · context
42 subjects.
Summary · context
Twice-daily PTH(1-34) 20 μg subcutaneous injection.
Report a problemFND-2909993903
04HumanNon-randomized trialEfficacy outcome
In adults with postoperative hypoparathyroidism, PTH(1-34) reduced serum phosphate from baseline to 6 months, with subsequent stability.
In plain wordsIn adults with postoperative hypoparathyroidism, teriparatide lowered blood phosphate compared with baseline, then levels remained stable.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseSerum phosphate
Study
n = 42
Comparator
Baseline
Outcome group
Electrolyte balance · Endocrine and hormones
Studied dose
20 μg twice daily · subcutaneous injection · 24 monthsAs given in this study (human).
Measurements
Phosphate
4.3 mg/dL
baseline
Phosphate
3.9 mg/dL
6 months
Source sentences
Summary
Phosphate levels gradually decreased from baseline to 6 months (4.3 ± 1.1 vs 3.9 ± 0.6 mg/dL, P < 0.019), remaining stable until 24 months.
4 context sentences(design, population, supporting numbers)
Summary · context
To investigate the effects of 24-month PTH(1-34) treatment in a homogeneous cohort of adult subjects with postoperative hypoparathyroidism and to evaluate QOL changes.
Summary · context
Prospective open-label study.
Summary · context
42 subjects.
Summary · context
Twice-daily PTH(1-34) 20 μg subcutaneous injection.
Report a problemFND-2909993904
05HumanNon-randomized trialMechanism
In adults with postoperative hypoparathyroidism, serum alkaline phosphatase increased from baseline during PTH(1-34) therapy.
In plain wordsIn adults with postoperative hypoparathyroidism, blood alkaline phosphatase increased during teriparatide treatment compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSerum alkaline phosphatase
Study
n = 42
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg twice daily · subcutaneous injection · 24 monthsAs given in this study (human).
Source sentences
Summary
Serum alkaline phosphatase and calcium excretion gradually increased from baseline to 24 months.
4 context sentences(design, population, supporting numbers)
Summary · context
To investigate the effects of 24-month PTH(1-34) treatment in a homogeneous cohort of adult subjects with postoperative hypoparathyroidism and to evaluate QOL changes.
Summary · context
Prospective open-label study.
Summary · context
42 subjects.
Summary · context
Twice-daily PTH(1-34) 20 μg subcutaneous injection.
Report a problemFND-2909993905
06HumanNon-randomized trialEfficacy outcome
In adults with postoperative hypoparathyroidism, urinary calcium excretion increased from baseline during PTH(1-34) therapy.
In plain wordsIn adults with postoperative hypoparathyroidism, urine calcium increased during teriparatide treatment compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseUrinary calcium excretion
Study
n = 42
Comparator
Baseline
Outcome group
Electrolyte balance · Kidney and urinary
Studied dose
20 μg twice daily · subcutaneous injection · 24 monthsAs given in this study (human).
Source sentences
Summary
Serum alkaline phosphatase and calcium excretion gradually increased from baseline to 24 months.
4 context sentences(design, population, supporting numbers)
Summary · context
To investigate the effects of 24-month PTH(1-34) treatment in a homogeneous cohort of adult subjects with postoperative hypoparathyroidism and to evaluate QOL changes.
Summary · context
Prospective open-label study.
Summary · context
42 subjects.
Summary · context
Twice-daily PTH(1-34) 20 μg subcutaneous injection.
Report a problemFND-2909993906
07HumanNon-randomized trialEfficacy outcome
In adults with postoperative hypoparathyroidism, all eight SF-36 domain scores improved during PTH(1-34) therapy.
In plain wordsIn adults with postoperative hypoparathyroidism, all reported quality-of-life domains improved during teriparatide treatment compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSF-36 domains
Study
n = 42
Comparator
Baseline
Outcome group
Quality of life · Whole body
Studied dose
20 μg twice daily · subcutaneous injection · 24 monthsAs given in this study (human).
Source sentences
Summary
Data from SF-36 showed a significant improvement in the mean scores of all eight domains (P < 0.001).
4 context sentences(design, population, supporting numbers)
Summary · context
To investigate the effects of 24-month PTH(1-34) treatment in a homogeneous cohort of adult subjects with postoperative hypoparathyroidism and to evaluate QOL changes.
Summary · context
Prospective open-label study.
Summary · context
42 subjects.
Summary · context
Twice-daily PTH(1-34) 20 μg subcutaneous injection.
Report a problemFND-2909993907

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.